Milestone Pharmaceuticals (NASDAQ:MIST – Free Report) had its price objective cut by Piper Sandler to $3.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.
Several other brokerages also recently commented on MIST. Wall Street Zen upgraded Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 14th. HC Wainwright reaffirmed a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Cantor Fitzgerald assumed coverage on Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.83.
Get Our Latest Stock Report on MIST
Milestone Pharmaceuticals Trading Up 11.4%
NASDAQ:MIST opened at $0.46 on Monday. The company has a market cap of $57.32 million, a P/E ratio of -0.61 and a beta of 1.07. The stock’s fifty day moving average price is $0.76 and its two-hundred day moving average price is $1.29. Milestone Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $3.06. The company has a debt-to-equity ratio of 3.25, a current ratio of 6.27 and a quick ratio of 7.92.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The firm had revenue of $2.96 million during the quarter, compared to analyst estimates of $1.00 million. Milestone Pharmaceuticals had a negative return on equity of 435.88% and a negative net margin of 1,860.76%. As a group, analysts expect that Milestone Pharmaceuticals will post -0.81 EPS for the current year.
Institutional Investors Weigh In On Milestone Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC grew its stake in Milestone Pharmaceuticals by 880.3% in the 3rd quarter. Virtu Financial LLC now owns 113,848 shares of the company’s stock worth $99,000 after buying an additional 102,235 shares in the last quarter. Waterloo Capital L.P. bought a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth $40,000. Pinnacle Wealth Planning Services Inc. bought a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth $68,000. Valeo Financial Advisors LLC raised its position in shares of Milestone Pharmaceuticals by 12.2% during the 3rd quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock valued at $127,000 after buying an additional 16,000 shares in the last quarter. Finally, RVW Wealth LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $994,000. 86.18% of the stock is owned by hedge funds and other institutional investors.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
Further Reading
- Five stocks we like better than Milestone Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
